Table 3.
A summary of the impact of added atezo carrier on the biodistribution of 89Zr-atezo in immunocompetent C57Bl/6J mice bearing B16 F10 xenografts. Significant elevation of the tumor to normal tissue ratio was observed due to co-injection with 15x or 30x molar excess of naked atezo compared to carrier free 89Zr-atezo (specific activity = 2.75 μCi/μg). The improvement was driven both by suppression of 89Zr-atezo binding in normal tissues, and elevation of 89Zr-atezo accumulation in tumor. No significant improvement in ratios was noted by elevating the dose of carrier from 15x to 30x. All data were collected 48 hours post injection of radiotracer formulation. Data represent the mean ± standard deviation.
| Molar excess of added atezo carrier | |||
|---|---|---|---|
| 0 | 15 | 30 | |
| Tumor:Spleen | 0.64 ± 0.7 | 1.68 ± 0.1 | 1.42 ± 0.4 |
| Tumor:Sm.Int. | 2.35 ± 0.3 | 7.01 ± 0.2 | 10.55 ± 2.7 |
| Tumor:Bone | 2.29 ± 0.5 | 5.07 ± 1.0 | 6.53 ± 2.1 |
| Tumor:Muscle | 15.28 ± 0.9 | 15.82 ± 2.1 | 18.47 ± 2.2 |